From Kirsten Bischoff, Opalesque New York:
Private investments in public equity (PIPE) managers expect to maintain the level at which they are currently investing in, or increase their investment activity over the next 12 to 18 months, according to a new survey by Kramer Levin Naftalis & Frankel LLP and Rodman & Renshaw LLC, and released by MergerMarket.
The firms, which surveyed US PIPE investors including private equity managers, venture capital investors, hedge fund managers and mutual fund investors, will also look overwhelmingly towards the lower mid-market range for opportunities. Over half of all the respondents expect PIPE demand to see its greatest demands within the healthcare, biotechnology and life sciences industry.
"The resurgence of the biotechs is because for an extended period of time the credit markets tightened up and many of the stocks in this sector were so depressed that even if they could get PIPE financing they didn't want it," Reid Drescher, Founder and Portfolio Manager at New York-based Cape One Financial which manages a PIPE hedge fund. The return of market liquidity as well as rising market caps have brought a resurgence of transactions within this space.
In addition to rising levels of activity in the biotech sector, Drescher has also seen an incre......................
To view our full article Click here